ArticleGenes & diseases2026
CCT2 enhances c-Myc stabilization to drive tumor progression and chemoresistance in head and neck squamous cell carcinoma.
Article in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CCT2, a vital subunit of the chaperonin-containing TCP-1 (CCT) complex, has emerged as a critical regulator of protein homeostasis and cancer progression. In this study, we highlight the essential role of CCT2 in head and neck squamous cell carcinoma (HNSCC), where it is overexpressed and strongly associated with poor prognosis, advanced clinical stages, and aggressive tumor behavior. Mechanistically, CCT2 interacts with and stabilizes the oncogenic c-Myc protein to drive tumor cell proliferation, migration, and invasion. Furthermore, CCT2 contributes to cisplatin resistance by regulating c-Myc-dependent pathways and cell cycle-related proteins. Notably, apoptotic vesicles derived from drug-resistant tumor cells transfer CCT2 to neighboring cells, further enhancing chemoresistance. These findings position CCT2 as a key driver of HNSCC progression and c-Myc-mediated oncogenic pathways, presenting it as a promising therapeutic target for overcoming drug resistance and improving treatment outcomes in HNSCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.